Owners, management and financials
CVR: 42523925
DKK -3,390,139
Gross profit
Net result: DKK -5,039,754
Kristian Helin (33,33-49,99%), Hannibal Innovation ApS (15-19,99%)
1 more
CVR · view owners
Karin Absalonsen
Board: Karin Absalonsen (chair) and 2 members
CVR · view management
Active
Founded 1 July 2021
CVR · view overview
1 employee
CVR · 2026
Director registered: Karin Absalonsen
CVR · 01/05/2026
View the full event history
Dania Therapeutics ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Karin Absalonsen. The board consists of Karin Absalonsen (chair), Kristian Helin and Michael Manchuan Li. The company is owned by Kristian Helin, Hannibal Innovation ApS and Vernalis (R&D) Limited. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -3,390,139 and a net result of DKK -5,039,754 compared with DKK -9,556,855 the year before. Equity in the 2025 report amounted to DKK -15,413,086.
Selskabets formål er at drive forsknings- og udviklingsvirksomhed inden for bioteknologi med henblik på udvikling og kommercialisering af lægemidler inden for cancer samt anden i forbindelse hermed stående virksomhed
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 0 | -5M | 3.5M | -15.4M | 1 | |
| 202401/01/2024 – 31/12/2024 | 0 | -9.6M | 7.1M | -10.4M | 1 | |
| 202301/01/2023 – 31/12/2023 | 0 | -8.7M | 15.1M | -1.2M | 1 |
Compared to 1.038 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorThe CVR number of Dania Therapeutics ApS is 42523925.
Dania Therapeutics ApS is owned by Kristian Helin, Hannibal Innovation ApS and Vernalis (R&D) Limited.
The management of Dania Therapeutics ApS consists of Karin Absalonsen.
The board of Dania Therapeutics ApS consists of Karin Absalonsen, Kristian Helin and Michael Manchuan Li, with Karin Absalonsen as chair.
In 2025, Dania Therapeutics ApS reported a gross profit of DKK -3,390,139.
Dania Therapeutics ApS had 1 employee in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Dania Therapeutics ApS has published its annual report for 2025. Revenue came to DKK 0, and the net result was DKK -5,039,754.
As of May 1, 2026, Karin Absalonsen is registered as director of Dania Therapeutics ApS.
As of May 1, 2026, Hamed Mozaffari Brodersen has stepped down as director of Dania Therapeutics ApS.
Dania Therapeutics ApS has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK -9,556,855.
Dania Therapeutics ApS has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -8,721,963.
As of January 15, 2024, Kristian Helin has joined the board of directors of Dania Therapeutics ApS.
As of January 15, 2024, Kim Andersen has left the board of directors of Dania Therapeutics ApS.
As of November 1, 2023, Michael Manchuan Li has joined the board of directors of Dania Therapeutics ApS.
As of November 1, 2023, Lars Michael Wood has left the board of directors of Dania Therapeutics ApS.
Dania Therapeutics ApS has published its interim report for the period July 1, 2021 to December 31, 2022.
As of December 14, 2022, Hannibal Innovation ApS is registered as an owner of Dania Therapeutics ApS with an ownership share of 15%.
As of December 14, 2022, is registered as an owner of Dania Therapeutics ApS with an ownership share of 25%.
As of August 26, 2022, Kristian Helin is registered as an owner of Dania Therapeutics ApS with an ownership share of 33%.
As of October 18, 2021, Kim Andersen has joined the board of directors of Dania Therapeutics ApS.
As of October 18, 2021, Lars Michael Wood has joined the board of directors of Dania Therapeutics ApS.
As of October 18, 2021, Kristian Helin has left the board of directors of Dania Therapeutics ApS.
As of July 1, 2021, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of Dania Therapeutics ApS.
As of July 1, 2021, Karin Absalonsen has joined the board of directors of Dania Therapeutics ApS.
As of July 1, 2021, Kristian Helin has joined the board of directors of Dania Therapeutics ApS.
As of July 1, 2021, Hamed Mozaffari Brodersen is registered as director of Dania Therapeutics ApS.
Dania Therapeutics ApS was founded on July 1, 2021.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 29418888
CVR 29769796
CVR 34688605
CVR 34892970
CVR 35047565
